Evolent Health Return on Equity (ROE) Growth & History (EVH)
Evolent Health's return on equity was −75.47% for fiscal 2025.
View full Evolent Health company overviewEvolent Health annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −75.47% | −69.51 pp |
| 2024 | 2024-12-31 | −5.96% | +5.77 pp |
| 2023 | 2023-12-31 | −11.73% | −9.26 pp |
| 2022 | 2022-12-31 | −2.47% | +3.26 pp |
| 2021 | 2021-12-31 | −5.73% | +37.44 pp |
| 2020 | 2020-12-31 | −43.17% | −14.03 pp |
| 2019 | 2019-12-31 | −29.14% | −24.25 pp |
| 2018 | 2018-12-31 | −4.89% | +2.19 pp |
| 2017 | 2017-12-31 | −7.08% | +16.55 pp |
| 2016 | 2016-12-31 | −23.63% | −126.37 pp |
| 2015 | 2015-12-31 | 102.74% | +553.96 pp |
| 2014 | 2014-12-31 | −451.22% | — |
Evolent Health quarterly return on equity
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −7.28% | −5.10 pp |
| Q1 2026 | 2026-03-31 | −6.56% | +0.11 pp |
| Q4 2025 | 2025-12-31 | −68.26% | −66.02 pp |
| Q3 2025 | 2025-09-30 | −2.40% | −0.19 pp |
| Q2 2025 | 2025-06-30 | −2.17% | −2.32 pp |
| Q1 2025 | 2025-03-31 | −6.67% | −5.04 pp |
| Q4 2024 | 2024-12-31 | −2.24% | +0.85 pp |
| Q3 2024 | 2024-09-30 | −2.21% | +0.10 pp |
| Q2 2024 | 2024-06-30 | 0.15% | +3.25 pp |
| Q1 2024 | 2024-03-31 | −1.63% | +0.38 pp |
| Q4 2023 | 2023-12-31 | −3.09% | −1.77 pp |
| Q3 2023 | 2023-09-30 | −2.31% | −2.60 pp |
| Q2 2023 | 2023-06-30 | −3.10% | −2.35 pp |
| Q1 2023 | 2023-03-31 | −2.02% | −1.20 pp |
| Q4 2022 | 2022-12-31 | −1.32% | −0.46 pp |
| Q3 2022 | 2022-09-30 | 0.29% | +2.42 pp |
| Q2 2022 | 2022-06-30 | −0.75% | +0.73 pp |
| Q1 2022 | 2022-03-31 | −0.82% | — |
| Q4 2021 | 2021-12-31 | −0.87% | +1.47 pp |
| Q3 2021 | 2021-09-30 | −2.13% | +3.72 pp |
| Q2 2021 | 2021-06-30 | −1.48% | +25.77 pp |
| Q4 2020 | 2020-12-31 | −2.34% | +17.10 pp |
| Q3 2020 | 2020-09-30 | −5.85% | −3.57 pp |
| Q2 2020 | 2020-06-30 | −27.25% | −24.41 pp |
| Q1 2020 | 2020-03-31 | −8.87% | −4.70 pp |
| Q4 2019 | 2019-12-31 | −19.44% | −17.92 pp |
| Q3 2019 | 2019-09-30 | −2.28% | −1.08 pp |
| Q2 2019 | 2019-06-30 | −2.83% | −1.88 pp |
| Q1 2019 | 2019-03-31 | −4.17% | −2.84 pp |
| Q4 2018 | 2018-12-31 | −1.53% | −0.23 pp |
| Q3 2018 | 2018-09-30 | −1.20% | +0.14 pp |
| Q2 2018 | 2018-06-30 | −0.95% | +1.15 pp |
| Q1 2018 | 2018-03-31 | −1.33% | +1.15 pp |
| Q4 2017 | 2017-12-31 | −1.30% | +1.46 pp |
| Q3 2017 | 2017-09-30 | −1.34% | +0.70 pp |
| Q2 2017 | 2017-06-30 | −2.10% | −0.55 pp |
| Q1 2017 | 2017-03-31 | −2.48% | +18.13 pp |
| Q4 2016 | 2016-12-31 | −2.75% | −2.12 pp |
| Q3 2016 | 2016-09-30 | −2.04% | −0.20 pp |
| Q2 2016 | 2016-06-30 | −1.55% | −111.93 pp |
| Q1 2016 | 2016-03-31 | −20.61% | — |
| Q4 2015 | 2015-12-31 | −0.64% | — |
| Q3 2015 | 2015-09-30 | −1.84% | — |
| Q2 2015 | 2015-06-30 | 110.38% | — |
Evolent Health return on equity trends
Over the last five fiscal years, Evolent Health's return on equity decreased from −43.17% to −75.47%, a change of −32.31 percentage points. The latest reported quarter, Q2 2026, shows −7.28%.
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Evolent Health source filings ↗